Compounds > 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan
Page last updated: 2024-08-02 08:52:55

17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan

Description

Cross-References

ID SourceID
PubMed CID9826034
CHEMBL ID485832
SCHEMBL ID17736072
MeSH IDM0367041

Synonyms (24)

Synonym
gtpl1669
2-[(1s,2s,13r,21r)-22-(cyclopropylmethyl)-2,16-dihydroxy-14-oxa-11,22-diazaheptacyclo[13.9.1.0^{1,13}.0^{2,21}.0^{4,12}.0^{5,10}.0^{19,25}]pentacosa-4(12),5,7,9,15(25),16,18-heptaen-7-yl]guanidine
LOPAC0_000559
NCGC00162187-01
gnti
NCGC00162187-02
5'-guanidinylnaltrindole
5'-guanidinonaltrindole
c5'-guanidinyl naltrindole
CHEMBL485832 ,
5''''-guanidinonaltrindole
bdbm50027039
guanidinonaltrindole
5`-guanidinonaltrindole
c5''''-guanidinyl naltrindole
5''''-guanidinylnaltrindole
CCG-204649
bdbm50346950
5'-guanidinonaltrindole di(trifluoroacetate) salt hydrate
SCHEMBL17736072
219655-56-8
2-[(1s,2s,13r,21r)-22-(cyclopropylmethyl)-2,16-dihydroxy-14-oxa-11,22-diazaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5(10),6,8,15,17,19(25)-heptaen-7-yl]guanidine
DTXSID101018243
SDCCGSBI-0050542.P002

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Nrf2Homo sapiens (human)Potency2.9093AID624149
glp-1 receptor, partialHomo sapiens (human)Potency0.9200AID624148
thioredoxin reductaseRattus norvegicus (Norway rat)Potency25.2487AID488773; AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency29.0810AID493107
USP1 protein, partialHomo sapiens (human)Potency66.0530AID504865; AID540327
GLS proteinHomo sapiens (human)Potency19.9526AID624146
DNA polymerase III, partialBacillus subtilisPotency29.9349AID485295
regulator of G-protein signaling 4Homo sapiens (human)Potency23.7781AID504845
ParkinHomo sapiens (human)Potency29.0929AID720573
arylsulfatase AHomo sapiens (human)Potency4.2562AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.2589AID504332
beta-2 adrenergic receptorHomo sapiens (human)Potency3.6626AID485366
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency58.0479AID485313
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency19.0115AID1347049
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency35.4813AID504847
chromobox protein homolog 1Homo sapiens (human)Potency28.1838AID488953
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency26.1216AID1347050
flap endonuclease 1Homo sapiens (human)Potency21.1923AID488816; AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency58.0479AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency23.2809AID2660; AID2666
M-phase phosphoprotein 8Homo sapiens (human)Potency2.1192AID488949
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency3.5481AID504327
Amyloid-beta precursor proteinHomo sapiens (human)Potency5.1735AID720559
Alpha-synucleinHomo sapiens (human)Potency5.8048AID652106
Ataxin-2Homo sapiens (human)Potency39.8107AID588378
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency3.0131AID485368

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Delta-type opioid receptorMus musculus (house mouse)Ki0.0240AID149085; AID149086; AID149248
Delta-type opioid receptorRattus norvegicus (Norway rat)Ki0.0355AID149248; AID149675
Mu-type opioid receptorRattus norvegicus (Norway rat)Ki0.0258AID151614; AID151766; AID152373; AID152386; AID152388; AID152389
Kappa-type opioid receptorRattus norvegicus (Norway rat)Ki0.0022AID148568; AID148575; AID148584; AID148585; AID148586; AID148588; AID148589; AID148590; AID148598; AID148599
Mu-type opioid receptorHomo sapiens (human)Ki0.0001AID152386
Delta-type opioid receptorHomo sapiens (human)Ki0.0001AID152386
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.0002AID149260
Kappa-type opioid receptorHomo sapiens (human)Ki0.0001AID152386; AID603174; AID603175
Serine/threonine-protein kinase mTORHomo sapiens (human)Ki0.0001AID603174

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Delta-type opioid receptorMus musculus (house mouse)Kd0.0155AID148383
Mu-type opioid receptorHomo sapiens (human)Kd0.0032AID151116
Delta-type opioid receptorHomo sapiens (human)Kd0.0155AID148383
Kappa-type opioid receptorHomo sapiens (human)Kd0.0000AID148169
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Kd0.0000AID148169

Other Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Delta-type opioid receptorMus musculus (house mouse)Ke0.1150AID148938; AID148939
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ke0.0002AID148975
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ke0.0300AID147889

Bioassays (81)

Assay IDTitleYearJournalArticle
AID227092Ratio of the IC50 of Kappa receptor agonist, ethylketazocine in the presence of compound in GPI divided by the control IC50.2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID148972Opioid antagonist potencies against Opioid receptor kappa 1 from guinea pig ileum employing ethylketazocine (EKC) as agonist.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
ISSN: 0022-2623		Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
AID148589Effect on binding to kappa(Glu297Ala) opioid receptor, using [3H]diprenorphine in transiently expressed rat HEK293 cells2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
ISSN: 0022-2623		Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
AID148575Binding affinity towards rat opioid receptor kappa 1 was determined using [3H]diprenorphine radioligand2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
ISSN: 0022-2623		Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
AID152389Displacement of [3H]- diprenorphine from mu-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
ISSN: 0022-2623		Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID381429Increase of JNK phosphorylation in U50488 treated untransfected HEK293 cells at 10 uM after 1 hr2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
ISSN: 0021-9258		Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.
AID149783Inhibition of [3H]-DADLE binding to Opioid receptor delta 1 of rat brain tissue2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
ISSN: 0022-2623		Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
AID148704Opioid antagonist potency, determined in the guinea pig ileum (GPI) preparation, by employing EK (kappa-opioid) as agonist, expressed as IC50 ratio (tested at 20 nM)2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
ISSN: 0022-2623		Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
AID148588Effect on binding affinity of mutational exchange of Glu297 in the Opioid receptor kappa 1 in transiently expressed rat cos-7 cells activity expressed as binding affinity.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
ISSN: 0022-2623		Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
AID149260Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of guinea pig brain2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
ISSN: 0022-2623		Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
AID603175Displacement of [125I]-IBNalA from KOR-1 expressed in CHO cells2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
ISSN: 1464-3405		Generation of novel radiolabeled opiates through site-selective iodination.
AID148975Opioid receptor kappa 1 Antagonism (100 nM) is expressed as (Ke = [antagonist] / (IC50 ratio -1)2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID152386Displacement of [3H]- diprenorphine from mu-K303E-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
ISSN: 0022-2623		Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID229883Selectivity ratio, ratio of binding affinity of mu to kappa opioid receptor2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID227093Ratio of the IC50 of delta receptor agonist, [D-Ala-2, D-Leu5]-enkephalin in the presence of compound in MVD divided by the control IC50.2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID756068Selectivity ratio of Ki for delta opioid receptor (unknown origin) to Ki for kappa opioid receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
ISSN: 1464-3405		Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.
AID756071Selectivity ratio of Ki for mu opioid receptor (unknown origin) to Ki for kappa opioid receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
ISSN: 1464-3405		Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.
AID148447Mutant factor against mutant receptor with Opioid receptor kappa 11998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
ISSN: 0022-2623		Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
AID149675Binding affinity on HEK293 cells transiently transfected with plasmids encoding the rat Opioid receptor delta 12000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID147887Opioid antagonist potencies against Opioid receptor mu 1 from guinea pig ileum employing morphine(M) as agonist.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
ISSN: 0022-2623		Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
AID147889Opioid receptor mu 1 Antagonism (100 nM) is expressed as (Ke = [antagonist] / (IC50 ratio -1)2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID152388Displacement of [3H]- diprenorphine from mu-W318A-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
ISSN: 0022-2623		Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID148973Opioid antagonist potency towards opioid receptor kappa 1 determined in guinea pig ileum preparation2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
ISSN: 0022-2623		Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
AID151766Effect on binding affinity of mutational exchange of Lys303 in the Opioid receptor mu 1 in transiently expressed rat cos-7 cells activity expressed as binding affinity.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
ISSN: 0022-2623		Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
AID149086Displacement of [3H]- diprenorphine from delta-W284E-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
ISSN: 0022-2623		Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID148446Effect on binding affinity of mutational exchange of Glu297 in the Opioid receptor kappa 1 in transiently expressed rat cos-7 cells activity expressed as binding ratio with nor-BNI.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
ISSN: 0022-2623		Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
AID152373Binding affinity towards rat mu-opioid receptor was determined using [3H]diprenorphine as radioligand2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
ISSN: 0022-2623		Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
AID233597Ratio of Ke value to kappa receptor to that of mu receptor1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
ISSN: 0022-2623		Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
AID148598Mutant factor of the compound against kappa[E297K] with Opioid receptor kappa 1 for binding affinity.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
ISSN: 0022-2623		Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
AID148786Opioid antagonist potency, determined in mouse vas deferens (MVD) preparation, using DADLE (delta-opioid) as agonist, expressed as IC50 ratio2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
ISSN: 0022-2623		Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
AID229881Selectivity ratio, ratio of Ke value of mu to kappa opioid receptor2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID229882Selectivity ratio, ratio of binding affinity of delta to kappa opioid receptor2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID151620Inhibition of [3H]DAMGO binding to Opioid receptor mu 1 of rat brain tissue2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
ISSN: 0022-2623		Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
AID148590Effect on binding to wild-type opioid receptor kappa 1 using [3H]diprenorphine in transiently expressed rat HEK293 cells2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
ISSN: 0022-2623		Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
AID229876Selectivity ratio, ratio of Ke value of Kappa to Delta opioid receptor (extrapolated value)2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID152219Opioid antagonist potency, determined in guinea pig ileum (GPI) preparation, using morphine (mu-opioid) as agonist, expressed as IC50 ratio2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
ISSN: 0022-2623		Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
AID233596Ratio of Ke value to kappa receptor to that of delta receptor1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
ISSN: 0022-2623		Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
AID415716Selectivity ratio of Ki for delta opioid receptor to Ki for kappa opioid receptor2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
ISSN: 1464-3405		14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
AID148169Antagonistic activity against human cloned kOpioid receptor kappa 1 using U69,593 in [35S]GTP-gamma-S, assay2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
ISSN: 0022-2623		Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
AID603174Displacement of [125I]-IBNtxA from KOR-1 expressed in CHO cells2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
ISSN: 1464-3405		Generation of novel radiolabeled opiates through site-selective iodination.
AID148585Displacement of [3H]diprenorphine from k-Y312A-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
ISSN: 0022-2623		Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID149248Binding affinity towards mouse delta-opioid receptor was determined using [3H]diprenorphine as radioligand2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
ISSN: 0022-2623		Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
AID148939Opioid antagonist potency, determined in mouse vas deferens (MVD) preparation, using DADLE (delta-opioid) as agonist (Ke=antagonist/IC50 ratio -1)2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
ISSN: 0022-2623		Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
AID233363Selectivity ratio of mu and kappa opioid receptor2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
ISSN: 0022-2623		Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
AID152223Opioid antagonist potency, determined in guinea pig ileum (GPI) preparation, using morphine (mu-opioid) as agonist (Ke=antagonist/IC50 ratio -1)2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
ISSN: 0022-2623		Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
AID779513Selectivity ratio of Ki for DOR (unknown origin) to Ki for KOR (unknown origin)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
ISSN: 1464-3391		Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opio
AID148383Antagonistic activity against human cloned Opioid receptor delta 1 using DPDPE in [35S]GTP-gamma-S, assay2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
ISSN: 0022-2623		Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
AID149085Displacement of [3H]- diprenorphine from delta receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
ISSN: 0022-2623		Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID148568Binding affinity on HEK293 cells transiently transfected with plasmids encoding the rat Opioid receptor kappa 12000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID151116Antagonistic activity against human cloned Opioid receptor mu 1 using DPDPE in [35S]GTP-gamma-S, assay2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
ISSN: 0022-2623		Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
AID381420Inhibition of U50488-induced analgesic activity against C57BL/6 mouse assessed as tail withdrawal latency at 10 mg/kg, ip upto 21 days2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
ISSN: 0021-9258		Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.
AID148584Displacement of [3H]diprenorphine from k-E297A-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
ISSN: 0022-2623		Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID148938Opioid antagonist potencies against Opioid receptor delta 1 from mouse vas-deferens preparation employing [D-Ala2,D-Leu5]enkephalin (DADLE) as agonist.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
ISSN: 0022-2623		Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
AID415715Selectivity ratio of Ki for mu opioid receptor to Ki for kappa opioid receptor2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
ISSN: 1464-3405		14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
AID148599Mutant factor of the compound against mu-[K303E] with Opioid receptor kappa 1 for binding affinity1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
ISSN: 0022-2623		Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
AID148586Displacement of [3H]diprenorphine from opioid receptor kappa 1 expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
ISSN: 0022-2623		Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID227211Ratio of the IC50 of mu receptor agonist, Morphine in the presence of compound in GPI divided by the control IC50.2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID779514Selectivity ratio of Ki for MOR (unknown origin) to Ki for KOR (unknown origin)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
ISSN: 1464-3391		Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opio
AID233141Selectivity ratio of delta and kappa opioid receptor2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
ISSN: 0022-2623		Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
AID151614Binding affinity on HEK293 cells transiently transfected with plasmids encoding the rat Opioid receptor mu 12000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID148942Opioid receptor delta 1 Antagonism (100 nM) is expressed as (Ke = [antagonist] / (IC50 ratio -1)2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
ISSN: 1552-454X		A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247		A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
ISSN: 1932-6203		Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
ISSN: 0021-9258		Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
ISSN: 1945-7170		A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
ISSN: 1946-6242		Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
ISSN: 1945-7170		A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
ISSN: 1932-6203		Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
ISSN: 1946-6242		Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
ISSN: 1932-6203		Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
ISSN: 1946-6242		Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60ISSN: 1873-3913A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1346329Human kappa receptor (Opioid receptors)2000European journal of pharmacology, May-12, Volume: 396, Issue:1
ISSN: 0014-2999		5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist.
AID1346329Human kappa receptor (Opioid receptors)2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623		Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (4.55)18.2507
2000's8 (36.36)29.6817
2010's8 (36.36)24.3611
2020's5 (22.73)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
pyrazolanthrone
1
anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector		2007200717.0low000100
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer
1
2011201113.0low000010
anisomycin
1
monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor		2007200717.0low000100
u-50488
1
dichlorobenzene;
monocarboxylic acid amide;
N-alkylpyrrolidine		analgesic;
antitussive;
calcium channel blocker;
diuretic;
kappa-opioid receptor agonist		2007200717.0low000100
naloxone
2
morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist		2007201115.0low000110
oxymorphone
1
morphinane alkaloid2001200123.0low000100
morphine
1
morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic		2011201113.0low000010
beta-funaltrexamine
1
morphinane alkaloid2009200915.0low000100
levallorphan
1
morphinane alkaloid2011201113.0low000010
naltrexone
5
cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic		2001201314.6medium000230
enkephalin, ala(2)-mephe(4)-gly(5)-
2
peptide2009201114.0low000110
norbinaltorphimine
7
isoquinolines1998201121.0high002410
naltrindole
6
isoquinolines1998201316.5medium001230
cyprodime
3
2009201312.3medium000120
6'-guanidinonaltrindole
1
2001200123.0medium000100
rimorphin
1
2007200717.0low000100
7-spiroindanyloxymorphone
1
2001200123.0medium000100
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Anemia, Fanconi0
1
201620168.0low000010
Congenital Zika Syndrome0
1
202020204.0low000010
Contact Dermatitis0
1
201920195.0low000010
Dermatitis, Contact0
1
201920195.0low000010
Disease Models, Animal0
2
201920204.5medium000020
Fanconi Anemia0
1
201620168.0low000010
Itching0
1
201920195.0low000010
Muscle Contraction0
1
2001200123.0low000100
Pruritus0
1
201920195.0low000010
Zika Virus Infection0
1
202020204.0low000010